Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28286606
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Aspects of Carbon Monoxide in Form of CO-Releasing Molecules Used in Cancer
Treatment: More Light on the Way
#MMPMID28286606
Kourti M
; Jiang WG
; Cai J
Oxid Med Cell Longev
2017[]; 2017
(?): 9326454
PMID28286606
show ga
Carbon monoxide (CO) has always been recognised as a toxic gas, due to its higher
affinity for haemoglobin than oxygen. However, biological studies have revealed
an intriguing role for CO as an endogenous signalling molecule, a
gasotransmitter. CO is demonstrated to exert many cellular activities including
anti-inflammatory, antiapoptotic, and antiproliferative activities. In animal
studies, CO gas administration can prevent tissues from hypoxia or
ischemic-reperfusion injury. As a result, there are a plethora of reports dealing
with the biological applications of CO and CO-releasing molecules (CORMs) in
inflammatory and vascular diseases. CORMs have already been tested as a
therapeutic agent in clinical trials. More recently, an increased interest has
been drawn to CO's potential use as an anticancer agent. In this review, we will
aim to give an overview of the research focused on the role of CO and CORMs in
different types of cancer and expand to the recent development of the next
generation CORMs for clinical application in cancer treatment.
|Animals
[MESH]
|Antineoplastic Agents/chemistry/metabolism/*therapeutic use
[MESH]
free
free
free
